Mato just raised pre-seed Read more
Podcast charts
Published by Psychedelic Alpha
The Psychedelic News Feed is the audio edition of Psychedelic Alpha's regular news roundup, bringing you a concise update from the worlds of psychedelic drug development, policy, and access. In it, Psychedelic Alpha Editor Josh Hardman provides a brief review of happenings across the field.
On the charts
Every published chart this podcast appears in, in the snapshot behind this page. Each one links to the chart it came off.
From the feed
The latest episodes published to this podcast’s own RSS feed. Titles and descriptions are the publisher’s.
In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories: Usona Institute files its psilocybin for major depressive disorder new drug application with FDA FDA approves NRx Pharmaceuticals’ preservative-free generic ketamine We share our analysis of 610 public comments on FDA’s psychedelics docket ICER is set to review Compass Pathways’ psilocybin for treatment-resistant depression More takeaways from The Psychedelic Healthcare Forum Other stories Read more: Usona Files Psilocybin for Depression NDA as Race With Compass Tightens Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending Pharma Moves In: Investors, Developers and Lilly’s Carole Ho at the Psychedelic Healthcare Forum Take part in Johns Hopkins’ psychedelic research survey The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks. This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com . Send us your questions and comments at pod@psychedelicalpha.com Read more and join our newsletter at https://psychedelicalpha.com Follow us on Instagram @psychedelicalpha , X @Psyched_Alpha , and LinkedIn . Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/
In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories: Early Notes from The Psychedelic Healthcare Forum FDA Floats an Ibogaine Trial Design, Asks Field for Input Compass Talks Pricing, Label and a Slow Launch New Mexico Nears Medical Psilocybin Launch Six More Potential Psychedelic Brand Names Read more: Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names The Psychedelic Practitioner Issue 7: Preparedness (Systems) The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks. This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com . Send us your questions and comments at pod@psychedelicalpha.com Read more and join our newsletter at https://psychedelicalpha.com Follow us on Instagram @psychedelicalpha , X @Psyched_Alpha , and LinkedIn . Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/
In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through another busy two-week period in the field, including: Oregon Health Authority’s decision to shelve its proposed doubling of fees levied on state-regulated psilocybin entities (ft. Taylor West, Exec. Director, Healing Advocacy ) California carves out $4.7M for psychedelic research The DEA again moves to schedule 5 tryptamines The PATH Caucus publishes its RFI white paper Stanford and UCSF researchers call for “more aggressive” blinding in psychedelic trials (ft. Joshua Woolley, UCSF) Read more: Psychedelic Bulletin 232: Oregon Backpedals Psilocybin Fee Hike; DEA Again Moves to Schedule 5 Tryptamines The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks. This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com . Send us your questions and comments at pod@psychedelicalpha.com Read more and join our newsletter at https://psychedelicalpha.com Follow us on Instagram @psychedelicalpha , X @Psyched_Alpha , and LinkedIn . Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/
In the first episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through a very busy two-week period in the field, including: Three meetings, or what I’m calling ‘Psychedelics Week’, in D.C.: FDA’s public hearing, an ibogaine-related meeting hosted by ARPA-H, and a congressional briefing A commentary published by top FDA staff outlining a model for psychedelic drug development New Zealand’s approval of two psychiatrists to prescribe MDMA And many other headlines, including: Definium Therapeutics’ Phase 3 LSD for generalised anxiety disorder readout, more data from Compass Pathways’ psilocybin for treatment-resistant depression program, Xylo’s neuroplastogen enters the clinic, Eli Lilly’s acquisition of AtaiBeckley closes, RFK Jr. hosts Bryan Hubbard on his podcast to talk ibogaine, and Usona Institute files a trademark on ‘Arumaya’ a potential brand name for its psilocybin candidate. Read more: No Questions Asked: FDA’s Psychedelics Public Hearing ‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop Psychedelic Bulletin 231 Field Notes #5: 'Psychedelics Week' in Washington D.C. Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks. This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com . Send us your questions and comments at pod@psychedelicalpha.com Read more and join our newsletter at https://psychedelicalpha.com Follow us on Instagram @psychedelicalpha , X @Psyched_Alpha , and LinkedIn . Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/
Ranking source
Apple Podcasts rankings via the Mato Topic Intelligence Platform.
Observed November 4, 2026.
Apple and Apple Podcasts are trademarks of Apple Inc., registered in the U.S. and other countries.
Pairs with
Bring this source into Mato to read its transferable patterns, then turn them into an original show for your own audience.